We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therap... ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.37 | 1.38576779026 | 26.7 | 28.12 | 25.89 | 114882 | 26.82380598 | CS |
| 4 | 0.08 | 0.296406076325 | 26.99 | 29.71 | 25.8 | 144942 | 27.68848293 | CS |
| 12 | -2.18 | -7.45299145299 | 29.25 | 30.405 | 23.63 | 142582 | 27.07961157 | CS |
| 26 | 2.87 | 11.8595041322 | 24.2 | 36.37 | 22.3 | 216900 | 26.74283573 | CS |
| 52 | 6.55 | 31.9200779727 | 20.52 | 36.37 | 14.35 | 166822 | 23.99101732 | CS |
| 156 | 3.07 | 12.7916666667 | 24 | 36.37 | 14.35 | 171589 | 23.7200218 | CS |
| 260 | 3.07 | 12.7916666667 | 24 | 36.37 | 14.35 | 171589 | 23.7200218 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
